The median number of HMA cycles administered was 5 (range 1–36), with a median of respectively 6 (range 1–36) and 4 cycles (range 1–20) for patients who received HMA therapy as frontline treatment and for R/R CBF-AML. Here, CEBPZ is linked to acute myeloid leukemia.